A carregar...
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety data, as well as the patient-focused perspective through qualit...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3760444/ https://ncbi.nlm.nih.gov/pubmed/24019749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S32145 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|